Skip to main content
. Author manuscript; available in PMC: 2018 Aug 10.
Published in final edited form as: Ann Surg Oncol. 2011 Aug 23;19(3):901–907. doi: 10.1245/s10434-011-2006-7

Table 1.

Distribution of clinicopathologic characteristics

Factor BCT (n = 224) Mastectomy (n = 327) P value
Age 0.4
    Median 51 50
    Range 28–76 24–80
Clinical tumor size (cm) (mean) 3.42 4.62 <0.001
Clinical stage <0.001
    I 13 (6%) 8 (2%)
    II 160 (71%) 140 (43%)
    III 51 (23%) 179 (55%)
Histology <0.01
    IDC 201 (90%) 255 (78%)
    ILC 7 (3%) 35 (11%)
    Mixed IDC/ILC 11 (5%) 29 (9%)
    Other 5 (2%) 8 (2%)
Grade 0.07
    I 9 (4%) 19 (6%)
    II 64 (29%) 120 (37%)
    III 150 (67%) 188 (57%)
    Unknown 1 (<1%) 0
ER <0.01
    Positive 131 (58%) 230 (70%)
    Negative 93 (42%) 97 (30%)
PR 0.10
    Positive 102 (46%) 172 (53%)
    Negative 122 (54%) 155 (47%)
HER 0.22
    Positive 27 (12%) 52 (16%)
    Negative 194 (87%) 273 (83%)
    Unknown 3 (1%) 2 (1%)
Margin status 0.04
    Negative 209 (93%) 316 (97%)
    Close (<2 mm)a 14 (6%) 6 (2%)
    Positive 1 (<1%) 5 (1%)
Residual tumor size (cm) <0.001
    0 22 (10%) 25 (8%)
    0–2 144 (64%) 118 (36%)
    >2 58 (26%) 184 (56%)
Positive lymph nodes <0.001
    0 126 (56%) 67 (20%)
    1–3 58 (26%) 101 (31%)
    4–9 28 (13%) 98 (30%)
    ≥10 12 (5%) 61 (19%) <0.001

ER estrogen receptor, PR progesterone receptor

a

Close included invasive cancer or ductal carcinoma in situ within 2 mm of the margin